Exploring Innovation in Alzheimer’s Disease Research Highlights from CTAD 2024 17th Clinical Trials on Alzheimer’s Disease (CTAD) Madrid (Spain) October 29 – November 1, 2024 Last week, our team travelled to Madrid to participate in the 17th Clinical Trials on Alzheimer’s Disease (CTAD) conference, where we had the opportunity to present our latest research and […]

The post Exploring Innovation in Alzheimer’s Disease Research: Highlights from CTAD 2024 appeared first on Cambridge Cognition.

CTAD24 | Posters & Content Madrid, Spain | 29 October – 1 November 2024 This week, our team traveled to Madrid to attend CTAD 2024, where they presented several posters and hosted a session on Validating Speech-Based Biomarkers for Measuring Disease Progression in Alzheimer’s Disease (AD). These materials are now available for you to access […]

The post CTAD24 | Posters & Content appeared first on Cambridge Cognition.

Highlights from the Clinical Trials Innovation Summit 2024 San Francisco, CA – 22nd October 2024 The 2024 Clinical Trials Innovation Summit, hosted by Genentech in San Francisco, gathered experts from across the clinical trial field to reimagine patient care through AI-driven innovation. Featuring industry leaders, clinicians, and researchers this event explored how technological advances and […]

The post Shaping the Future of Patient-Centric, AI-Driven Research appeared first on Cambridge Cognition.

CTAD24 | Clinical Trials on Alzheimer’s Disease Madrid, Spain | 29 October – 1 November 2024 Be the first to gain access to new data and insights, presented at CTAD24. This year at CTAD, we can’t wait to share our latest research with you. There will be four posters, with Michael Spilka, PhD taking us […]

The post CTAD24 | Clinical Trials on Alzheimer’s Disease appeared first on Cambridge Cognition.

Revolutionizing Clinical Trial Central Monitoring: Automated Quality Assurance for Faster, Scalable Monitoring by Rachel Newsome, PhD Tuesday 22nd October at 15:45  Accurate administration of rater-based clinical instruments, such as the Clinical Dementia Rating (CDR), is critical for reliable clinical outcomes in Alzheimer’s Disease (AD) trials. However, existing gold-standard quality assurance (QA) processes rely heavily or […]

The post Clinical Trials Innovation Summit 2024 appeared first on Cambridge Cognition.

We caught up with the 2023 CANTAB® Research Grant Winner, Dr Simran Kaur, from the All India Institute of Medical Sciences, New Delhi, India. She shares with us how the grant will help to non-invasively explore the neural underpinnings to establish state and trait markers in neuropsychiatric and neurodegenerative disorders. I, Dr Simran Kaur sincerely […]

The post 2023 CANTAB Research Grant Winner: Assessment of cognitive function in patients of breast cancer on chemotherapy: A prospective longitudinal study at tertiary care centre in India appeared first on Cambridge Cognition.

We’re thrilled to have presented our latest research at the ISCTM Autumn Meeting on 12-13 September 2024. Rachel Newsome, PhD shared research into the future of clinical trials with recent validation of AQUA, innovation in cognitive assessments, and cutting-edge methodologies. Download poster If you have any questions or would like to discuss any of our […]

The post ISCTM 2024: Analytical validation of a novel quality assurance approach for COAs in Alzheimer’s Disease clinical trials appeared first on Cambridge Cognition.

Cambridge, UK—10 July 2024: Cambridge Cognition, a leading provider of digital health solutions for brain health assessments has been included in the Bio-Hermes-002 project for its voice and touch-screen cognitive assessments, funded by the UK’s innovation agency, Innovate UK.  The Bio-Hermes-002 trial, led by the Global Alzheimer’s Platform Foundation (GAP), aims to determine how accurately digital […]

The post Cambridge Cognition secures Innovate UK grant to collect multimodal data with a large patient sample in the Bio-Hermes-002 project appeared first on Cambridge Cognition.

We’ve joined forces with ESSEXLab at the Centre for Behavioural Science (CBS), University of Essex, to gather normative data from latency-based and rater-scored tasks like our Reaction Time (RTI) task and Verbal Recognition Memory (VRM). This partnership will significantly enrich our normative offerings further and provide robust benchmarks, demonstrating the sensitivity in CANTAB endpoints. Our […]

The post New partnership with the University of Essex to strengthen CANTAB® normative data offering appeared first on Cambridge Cognition.

Cambridge, UK – 30 April 2024: Cambridge Cognition, a leading provider of digital health solutions for brain health assessment, has announced that The Michael J. Fox Foundation for Parkinson’s Disease Research will incorporate its CANTAB® cognitive assessments into the Parkinson’s Progression Markers Initiative (PPMI).  The landmark initiative will use Cambridge Cognition’s technology to identify the cognitive […]

The post Cambridge Cognition and The Michael J. Fox Foundation to employ digital cognitive assessments in unraveling the mysteries of Parkinson’s disease appeared first on Cambridge Cognition.

by Martina De LilloClinical ScientistCambridge Cognition Disorders of the Central Nervous System (CNS) affect billions of people worldwide (The Lancet Neurology, 2022), representing an important cause of death and disability around the world. Life expectancy has been extended in the last years which has increased the number of brain pathologies related to aging, such as […]

The post Supporting research into central nervous system (CNS) disorders to improve patient quality of life appeared first on Cambridge Cognition.

Cambridge, UK – 23 April 2024: Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that Monument Therapeutics Limited (“Monument”) a precision neuroscience company spun-out from, and partly owned by Cambridge Cognition, has completed a £1.0 million fundraise and announced a further £0.5 million grant […]

The post Cambridge Cognition spin-out Monument Therapeutics accesses £1.5m for schizophrenia clinical development appeared first on Cambridge Cognition.

We caught up with the 2023 CANTAB Research Grant Secondary Award Winner, Louise Engelbrecht, who tells us how the grant will help to provide a better understanding of cognitive function during ultra-endurance performance and the role of ketone ester supplements to retain cognitive function. ​ I was elated when I got the news about receiving […]

The post 2023 CANTAB Research Grant: Exploring the role of intermittent exogenous ketosis on physical and mental fatigue during ultra-endurance performance appeared first on Cambridge Cognition.

Cambridge, UK – 10 April 2024: Cambridge Cognition, a leader in digital health solutions for brain health assessment, has announced the appointments of Alex Livingstone-Learmonth as Chief Commercial Officer and Annabelle Miles as Head of Marketing. These strategic additions mark a significant step as the Company continues strengthening its senior leadership team in pursuit of […]

The post Cambridge Cognition strengthens senior management team to deliver growth appeared first on Cambridge Cognition.

We caught up with the 2023 CANTAB™ Research Grant Secondary Award Winner, Eduardo López-Caneda, from the School of Psychology at the University of Minho​who. He shares with us how the grant will help to understand cognitive training and neuromodulation as a potential strategy to modify alcohol consumption habits. I am deeply grateful to Cambridge Cognition […]

The post 2023 CANTAB Research Grant: The microbiota-gut-brain axis in young binge drinkers: The interplay between alcohol use, microbiota composition and neurocognitive functioning appeared first on Cambridge Cognition.

Cambridge, UK – 21 March 2024: Cambridge Cognition, a leader in digital health solutions for brain health assessment, announces the formation of a Scientific Advisory Board (SAB). This expert board will provide scientific guidance and valuable market insights, primarily focusing on addressing emerging trends such as the integration of blood-based biomarkers and the collaborative possibilities […]

The post Cambridge Cognition announces scientific advisory board appeared first on Cambridge Cognition.

Schizophrenia spectrum disorders are complex and serious psychiatric disorders with multifaceted symptoms and associated difficulties, including psychosis, negative symptoms (e.g., loss of motivation), cognitive dysfunction, and functional impairment in major life areas. This multifaceted clinical picture in schizophrenia is also heterogeneous, both across individuals and within individuals over time, posing a challenge for studying groups […]

The post Digital measures to advance research & quality of life in schizophrenia appeared first on Cambridge Cognition.

The post AARDEX and Cambridge Cognition join forces to bring next-level adherence oversight to hybrid and decentralized clinical trials appeared first on CLINPAL – Engaging Patients in Clinical Research.

The post eClinicalHealth is pleased to announce its acquisition by Cambridge Cognition appeared first on CLINPAL – Engaging Patients in Clinical Research.

The post eClinicalHealth, Ltd. adds SAPASI instrument to its Clinpal library of DCT, ePRO tools appeared first on CLINPAL – Engaging Patients in Clinical Research.